IDENTIFY Study Participants – 5-Base Sample Preparation and Whole Genome Multiomic Profiling

The National Institutes of Health National Human Genome Research Institute is conducting a sole-source acquisition for 5-base sample preparation and whole genome multiomic profiling services supporting the IDENTIFY study, with capability statements due September 15, 2026 at 12:00 PM EST. The Prenatal Genomics and Therapy Section intends to award a purchase order to The Broad Institute on a noncompetitive basis for high-resolution sequencing of stored plasma-derived cell-free DNA samples collected from women who received prenatal sequencing results suggestive of maternal malignancy. The government determined that The Broad Institute is the only reasonably available source due to the ongoing nature of the research and the requirement to maintain scientific continuity with previously generated data; introducing another source could compromise study validity through unknown variables and methodological inconsistencies. The contractor will perform 5-base sample preparation, conduct whole genome multiomic profiling at 30x, generate genomic and epigenomic data, perform quality-control activities, and deliver resulting data and technical documentation in mutually agreed electronic formats. Work is performed at the contractor's facility with deliverables submitted to NHGRI in Bethesda, Maryland. The period of performance is 12 months from an anticipated award date of September 25, 2026. The acquisition is below the Simplified Acquisition Threshold and is not set-aside. Despite the stated sole-source intent, the government is accepting capability statements from other sources addressing experience with 5-base sequencing of cell-free DNA, technical capability, quality-control processes, and ability to maintain scientific continuity. NAICS 541380; small business size standard $19.5 million.